Appendix 4C Revised
Filed with ASX · · 12 pages · English
Summary by 6ix AI
The report highlights record quarterly revenue and cash receipts, alongside positive cash flow from operating activities. Key agreements were established, including partnerships for the import and manufacture of medicinal cannabis products, positioning the company for growth in emerging markets. The filing also notes the successful dual listing on the Frankfurt Stock Exchange, enhancing access for European investors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/appendix-4c-revised
• Record $18.4 million quarterly Cash Receipts, representing a 149% increase on Q2 FY25 and a 43% increase on Q1 FY26. • $2.5 million positive Q2 cash flow from operating activities • Completed dual listing on the Frankfurt Stock Exchange (ticker: PR8.F) on 13 October 2025, enhancing liquidity and access for European investors • Executed exclusive import, manufacture, and supply agreement with Cur
In the deck
Story so far
Earlier from Bioxyne
- Quarterly Activities/Appendix 4C Cash Flow Report
- Supply Agreement Secured - Central American Cannabis Markets
- Funding from SOSE to Establish UK GMP Manufacturing Facility
- BLS to Manufacture and Distribute Curaleaf International MID
- Presentation on FY2025 Quarter 1 Results
Later from Bioxyne
- Presentation Results Q2 FY2026
- Half Yearly Report and Accounts
- Stronger H1 FY2026 Performance Upward Revision to Guidance
- BXN H1 FY2026 Results Presentation
- Bioxyne Signs Manufacturing Agreement with Aurora Cannabis
Follow Bioxyne into a list and get an email when it puts out news.
Follow Bioxyne